IBA announced on October 21, 2026, that the first patient had been treated in its ConformalFLASH trial at Penn Medicine. The company-sponsored study is testing the feasibility of an investigational proton therapy approach for patients who need repeat radiation treatment for head and neck cancer.
Key Takeaways
- C-FLASH-01 has begun treating patients under an FDA-authorized Investigational Device Exemption.
- The study targets patients requiring head and neck cancer re-irradiation who cannot undergo surgical resection.
- Potential clinical benefits remain under investigation; the announcement provides no treatment-outcome data.
Table of Contents
- What the ConformalFLASH trial is testing
- A development milestone, not an efficacy result
- Specialist suppliers support treatment delivery
- Conclusion
What the ConformalFLASH trial is testing
IBA’s first-patient announcement identifies C-FLASH-01, registered as NCT07644585, as the first human feasibility study of its ConformalFLASH proton therapy. The study uses fractionated treatment delivered with Bragg peak proton beams.
The technology is designed to combine the physical precision of proton therapy with ultra-high dose rate delivery. The trial will evaluate whether that approach can be delivered to patients requiring re-irradiation for head and neck cancer who are not amenable to surgical resection.
Penn Medicine is conducting the study under an Investigational Device Exemption authorized by the U.S. Food and Drug Administration. That authorization permits the clinical investigation; it does not establish that the treatment provides a clinical benefit.
| Item | Details |
|---|---|
| RaySearch Laboratories | Provides a research version of its FLASH treatment-planning system. |
| 3D Systems | Supports 3D printing of patient-specific devices, including the ConformalFLASH Energy Modulator. |
| .decimal | Supplies precision-milled patient-specific apertures. |
| IBA Dosimetry | Develops FLASH-enabled dosimetry solutions, including FLASH Lynx and MatriXX Air. |
A development milestone, not an efficacy result
For Belgium-based IBA, the first treatment moves ConformalFLASH into human clinical evaluation. The Euronext-listed company is both the technology developer and the trial sponsor, extending its role beyond supplying equipment to supporting the generation of clinical evidence.
Chief Executive Olivier Legrain said IBA was actively supporting the technology’s clinical evaluation alongside its clinical partners. The company said evidence from C-FLASH-01 may inform further development and potential integration into clinical proton therapy workflows.
ConformalFLASH remains under research and development. IBA did not disclose patient outcomes, an enrollment target or a results timetable in the announcement, so the milestone does not yet establish treatment effectiveness or a commercial rollout schedule.
Specialist suppliers support treatment delivery
The study brings together treatment-planning software, patient-specific manufactured components and radiation-measurement technology. The collaborators’ roles span preparation and delivery of the investigational treatment.
Conclusion
The next evidence to watch is the trial’s assessment of treatment feasibility. IBA has not announced when results will be available, and any clinical benefit remains to be demonstrated.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
